MV
Medicxi Ventures Management (Jersey) Ltd 13F Filings Explorer
Medicxi Ventures Management (Jersey) LtdCIK: 0001715579
Concentrated strategyQuality / disciplined sizing
Total reported value
$981.8M
Reporting period: 2026-03-31 · Number of holdings: 4
Medicxi Ventures Management (Jersey) Ltd disclosed 4 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $981.8M and a quarterly turnover rate of 49.3%.
Browse other institutions with $100M to $1B AUMBrowse other institutions starting with "M"
Personality snowflake
- Concentration
- 100
- Portfolio Stability
- 49.32
- Momentum/Contrarian
- 50
- Sector conviction
- 0
- Diversification
- 8
- Sizing Uniformity
- 85.08
Sector classification currently covers about 0% of this portfolio's disclosed value; the remainder includes holdings (e.g. unmapped tickers, options, or other security types) not yet covered by our sector mapping.
Recent moves
Add 260
0.0% $293.7M
Trim PHAT
0.0% -$40.9M
Trim NAMS
-6.8% -$15.1M
Add AURA
0.0% $3.8M
Sold out 75382E109
Holdings Map
New buyAddUnchangedTrim
Top 10 holdings by weight
Full holdings list this quarter
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 80.76% | +20.96% | — | |
| 2 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 8.72% | -3.34% | -6.81% | |
| 3 | PHAT | Phathom Pharmaceuticals INC | Stock-Other | 8.45% | -6.38% | — | |
| 4 | AURA | Aura Biosciences INC | Stock-Other | 2.07% | +0.09% | — |
Portfolio Performance
Performance for Q3 2026
—
Performance Last 4 Quarters
—
Based on 4 months of available history
Based on 19% of reported portfolio value with available pricing
- Stdev
- +18.4%
- Beta
- +0.62
- Alpha
- -71%
- Max Drawdown
- -20%
- Annualized Perf
- -52%
- Batting Avg vs S&P
- 0%
- Sortino
- -2.72
- Stutzer
- —
- Treynor
- -1.12
- Sterling
- —
- Calmar
- -2.59
- Information Ratio
- -4.74
- Tracking Error
- +15.1%
- Stdev Down
- +25.7%
- Winning Months %
- 0%
- Losing Months %
- +100%
- Best 12 Months
- —
- Worst 12 Months
- —
- Efficiency Ratio
- +0.93
- Sharpe
- -3.79
- Stdev Sectors
- —
- Skewness
- -0.56
- Kurtosis
- -1.28
- Upside Potential
- 0
Reported value over time
Sector allocation
Not enough sector-mapped data yet
Sector allocation over time
Quarterly history
| Period | Holdings | Total value | Stability | Top holdings |
|---|---|---|---|---|
| 2026-03-31 | 4 | $981.8M | 49 | |
| 2025-12-31 | 5 | $835.0M | 12 | |
| 2025-09-30 | 5 | $744.4M | 52 | |
| 2025-06-30 | 5 | $427.3M | 0 | |
| 2025-03-31 | 5 | $437.7M | 100 | |
| 2024-12-31 | 5 | $529.0M | 0 | |
| 2024-09-30 | 4 | $528.9M | 0 | |
| 2024-06-30 | 4 | $335.3M | 0 | |
| 2024-03-31 | 5 | $449.2M | 0 | |
| 2023-12-31 | 5 | $296.2M | 0 | |
| 2023-09-30 | 6 | $313.2M | 0 | |
| 2023-06-30 | 6 | $356.9M | 0 | |
| 2023-03-31 | 6 | $233.4M | 0 | |
| 2022-12-31 | 6 | $238.1M | 0 | |
| 2022-09-30 | 6 | $240.2M | 0 | |
| 2022-06-30 | 7 | $240.8M | 0 | |
| 2022-03-31 | 7 | $369.1M | 0 | |
| 2021-12-31 | 7 | $399.6M | 0 | |
| 2021-09-30 | 6 | $459.6M | 0 | |
| 2021-06-30 | 6 | $558.0M | 47 | |
| 2021-03-31 | 5 | $171.7M | 19 | |
| 2020-12-31 | 5 | $172.1M | 34 | |
| 2020-09-30 | 5 | $209.4M | 38 | |
| 2020-06-30 | 4 | $162.7M | 72 | |
| 2020-03-31 | 3 | $76.5M | 72 | |
| 2019-12-31 | 4 | $163.2M | 0 |
Holding changes this quarter
Medicxi Ventures Management (Jersey) Ltd's most significant position changes for 2026-03-31: Sold out: Rapt Therapeutics INC; Trim: NewAmsterdam Pharma Company N.V. (NAMS) — shares -6.81%.
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | 260 | Centessa Pharmaceuticals-adr | +21% | — | Unchanged |
| 2 | AURA | Aura Biosciences INC | +0.1% | — | Unchanged |
| 3 | NAMS | NewAmsterdam Pharma Company N.V. | -3.3% | -6.81% | Trim |
| 4 | PHAT | Phathom Pharmaceuticals INC | -6.4% | — | Unchanged |
| 5 | ✓ | Rapt Therapeutics INC | — | EXIT | Sold out |
Filing History
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2026-03-31 | 2026-04-21 | 13F-HR | View on EDGAR |
| 2025-12-31 | 2026-01-23 | 13F-HR | View on EDGAR |
| 2025-09-30 | 2025-10-17 | 13F-HR | View on EDGAR |
| 2025-06-30 | 2025-07-08 | 13F-HR | View on EDGAR |
| 2025-03-31 | 2025-04-11 | 13F-HR | View on EDGAR |
| 2024-12-31 | 2025-01-23 | 13F-HR | View on EDGAR |
| 2024-09-30 | 2024-10-15 | 13F-HR | View on EDGAR |
| 2024-06-30 | 2024-07-16 | 13F-HR | View on EDGAR |
| 2024-03-31 | 2024-04-15 | 13F-HR | View on EDGAR |
| 2023-12-31 | 2024-02-01 | 13F-HR | View on EDGAR |
| 2023-09-30 | 2023-10-18 | 13F-HR | View on EDGAR |
| 2023-06-30 | 2023-07-19 | 13F-HR | View on EDGAR |
| 2023-03-31 | 2023-04-27 | 13F-HR | View on EDGAR |
| 2022-12-31 | 2023-01-31 | 13F-HR | View on EDGAR |
| 2022-09-30 | 2022-10-25 | 13F-HR | View on EDGAR |
| 2022-06-30 | 2022-08-03 | Amendment | View on EDGAR |
| 2022-06-30 | 2022-08-03 | 13F-HR | View on EDGAR |
| 2022-03-31 | 2022-05-12 | 13F-HR | View on EDGAR |
| 2021-12-31 | 2022-02-03 | 13F-HR | View on EDGAR |
| 2021-09-30 | 2021-11-10 | 13F-HR | View on EDGAR |
| 2021-06-30 | 2021-08-03 | 13F-HR | View on EDGAR |
| 2021-03-31 | 2021-05-11 | 13F-HR | View on EDGAR |
| 2020-12-31 | 2021-02-12 | 13F-HR | View on EDGAR |
| 2020-09-30 | 2020-10-27 | 13F-HR | View on EDGAR |
| 2020-06-30 | 2020-08-07 | 13F-HR | View on EDGAR |
| 2020-03-31 | 2020-05-12 | 13F-HR | View on EDGAR |
| 2019-12-31 | 2020-02-11 | 13F-HR | View on EDGAR |
FAQ
What is Medicxi Ventures Management (Jersey) Ltd and what type of investor is it?
Medicxi Ventures Management (Jersey) Ltd is a investment manager that files SEC Form 13F quarterly, disclosing its U.S. public equity holdings to regulators. As of the most recent reporting period (2026-03-31), the firm manages a tracked equity portfolio valued at approximately $981.8M, spread across 4 disclosed positions.
What are Medicxi Ventures Management (Jersey) Ltd's largest equity positions?
Based on the latest 13F filing, Medicxi Ventures Management (Jersey) Ltd's top holdings by market value are:
1. Centessa Pharmaceuticals-adr (260) — $792.9M (80.8%)
2. NewAmsterdam Pharma Company N.V. (NAMS) — $85.6M (8.7%)
3. Phathom Pharmaceuticals INC (PHAT) — $82.9M (8.4%)
4. Aura Biosciences INC (AURA) — $20.3M (2.1%)
What changes did Medicxi Ventures Management (Jersey) Ltd make in its most recent portfolio filing?
In the latest quarter, Medicxi Ventures Management (Jersey) Ltd took a more defensive posture — trimming 1 positions and completely exiting 1 holdings. The largest of these moves: Sold out: Rapt Therapeutics INC; Trim: NewAmsterdam Pharma Company N.V. (NAMS) — shares -6.81%
What sectors does Medicxi Ventures Management (Jersey) Ltd focus on?
Sector breakdown data is not yet available for Medicxi Ventures Management (Jersey) Ltd. Check back after the next 13F processing cycle.
Peer Institutions
Institutions with a similar AUM
EW
Evolution Wealth Advisors, LLC
CIK 0001763121
Total reported value
$981.5M
176 stks
2026-03-31
Concentration41.4
Portfolio Stability9.4
Sector conviction100.0
AUM within 0.0% of this institution
View detail
R&
Rodgers & Associates, LTD
CIK 0001846515
Total reported value
$982.2M
101 stks
2026-03-31
Concentration15.8
Portfolio Stability4.2
Sector conviction67.1
AUM within 0.0% of this institution
View detail
BI
Blueprint Investment Partners LLC
CIK 0001794467
Total reported value
$980.4M
131 stks
2026-03-31
Concentration20.9
Portfolio Stability40.7
Sector conviction78.7
AUM within 0.1% of this institution
View detail
Similar Holdings Style
Institutions with overlapping top holdings
PA
Perceptive Advisors LLC
CIK 0001224962
Total reported value
$5.1B
94 stks
2026-03-31
Concentration16.4
Portfolio Stability54.7
Sector conviction100.0
1 of the top 5 holdings overlap, including Centessa Pharmaceuticals-adr
View detail
MC
Matrix Capital Management Company, LP
CIK 0001410830
Total reported value
$46.3M
1 stks
2026-03-31
Concentration100.0
Portfolio Stability54.8
Sector conviction0.0
1 of the top 5 holdings overlap, including Aura Biosciences INC
View detail
Carlyle Group Inc.
CIK 0001527166
Total reported value
$10.6B
20 stks
2026-03-31
Concentration100.0
Portfolio Stability24.4
Sector conviction100.0
1 of the top 5 holdings overlap, including Phathom Pharmaceuticals INC
View detail